ANT-GROUP
5.7.2024 12:27:25 CEST | Business Wire | Press release
Ant Group today unveiled SecretFlow Cloud, its cloud-based cryptographic computing platform, and a suite of cryptographic computing solutions tailored for large language models (LLMs) at the World Artificial Intelligence Conference in Shanghai.
Leveraging integrated software-hardware cryptographic computing technologies, these solutions enable the secure circulation of encrypted data throughout the hosting and inference processes of LLMs, safeguarding the integrity of LLM assets and data security while significantly enhancing data privacy protection. Providers can now encrypt and deploy their LLMs onto cloud environments effortlessly with a single click through its encrypted hosting service, safeguarding their valuable assets from compromise and theft. Meanwhile, the encrypted inference service ensures efficient data security and the protection of trade secrets during interactions with LLMs.
These solutions allow GPUs to perform computing tasks within trusted execution environments, notably reducing the cost and performance disparity between encrypted LLM inference and plaintext operations, providing a more cost-effective approach. The platform also integrates additional technologies such as memory and disk encryption, ensuring end-to-end encryption and secure cross-domain model hosting management. Additionally, a user-friendly remote attestation system allows for smooth verification through web interfaces, minimizing friction for users.
SecretFlow Cloud currently supports both public and private cloud deployments, and is compatible with commonly-used LLMs in the global market. For instance, in a public cloud setup, users can seamlessly build a new professional LLM on SecretFlow Cloud or migrate an existing LLM to the platform, with its secure LLM inference services ready in as few as 10 minutes with just a click. Moreover, users can purchase cryptographic computing resources on demand to meet their needs.
"Data is the most critical element in the application of LLMs, and cryptographic computing technology significantly enhances the utility of data in cross-domain scenarios," noted Dr. Lenx Wei, Vice President and Chief Technology Security Officer at Ant Group. "As LLMs evolve toward specialized professional domains and become essential productivity tools, cryptographic computing will play a vital role, particularly in fully unlocking the value of high-quality, domain-specific data sets."
According to Dr. Wei, while companies often deploy LLMs in private environments to address data security challenges, such methods can incur higher operational costs and compromise both service efficiency and quality, ultimately constraining the potential of LLMs. The cryptographic computing solutions offered by SecretFlow Cloud can effectively resolve these issues.
Looking forward, SecretFlow Cloud aims to further develop its cryptographic computing solutions to ensure data security throughout the full lifecycle of professional LLMs, including their creation, deployment, and service delivery.
Ant Group has been exploring privacy-preserving computing technologies since 2016 and released SecretFlow in 2022 as an open-source privacy-preserving computing framework that features an array of advanced technologies, including multiparty computation, federated learning, Trusted Execution Environments, Homomorphic Encryption, and Differential Privacy. Positioned at the forefront of cryptographic computing, SecretFlow Cloud represents a new generation of privacy-preserving computing technology, poised to overcome pain points in security, cost, and accessibility in data circulation. It offers a solution for instantly harnessing data value, akin to turning on a tap. To date, its technologies have been adopted in industries such as insurance, rural finance, healthcare, public services, and marketing.
About Ant Group
Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, we strive to provide all consumers and small and micro businesses equal access to digital financial and other daily life services that are convenient, sustainable and inclusive.
For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240705154761/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
